Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

cancer drugs pricing

- PMLiVE

Novartis’ ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Approximately half of those with Sjögren’s disease are thought to be undiagnosed

- PMLiVE

Novartis agrees to lower drug prices in deal with US government

In 2025, the pharma company announced a $23bn US investment commitment

- PMLiVE

Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

Around 9,000 people in the US currently live with SMA

- PMLiVE

Novartis announces plans for new US manufacturing hub

The US hub is expected to create 700 new jobs by 2030

- PMLiVE

Novartis reports primary endpoint reached in phase 3 malaria trial

The treatment demonstrated non-inferiority to current standard of care

- PMLiVE

Novartis presents new positive data for rheumatic autoimmune disease treatment

Patient outcome benefits were observed in two ongoing phase 3 trials

- PMLiVE

Novartis to acquire Avidity Biosciences in deal worth $12bn

The acquisition will expand Novartis’ neuroscience pipeline

- PMLiVE

La Roche-Posay launches global campaign to spotlight the visible and invisible impact of scars

‘Scars of Life’ aims to raise awareness of the psychological burden associated with skin conditions and scarring

- PMLiVE

From Burnout to Balance: New Campaign Focuses on the ‘Matters’ that are Really Affecting Our ‘Minds’ in Health Communications

Launched on World Mental Health Day, Minds on Matters aims to highlight mental wellbeing challenges while showcasing practical solutions and positive change

Fox&Cat

- PMLiVE

Novartis announces new data supporting MS therapy Kesimpta

The latest trial results reinforce the drug's long-term efficacy and safety profile

- PMLiVE

Novartis to acquire Tourmaline Bio in a deal worth $1.4bn

Novartis will gain cardiovascular treatment option pacibekitug

- PMLiVE

Novartis’ ianalumab shows promise in phase 3 Sjögren’s syndrome studies

The systemic autoimmune disease affects approximately 0.6% of the UK’s adult population

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links